

Kelly L Walton

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7481161/publications.pdf>

Version: 2024-02-01

46
papers

2,070
citations

279487

23
h-index

243296

44
g-index

47
all docs

47
docs citations

47
times ranked

3301
citing authors

#	ARTICLE	IF	CITATIONS
1	Human INHBB Gene Variant (c.1079T>C;p.Met360Thr) Alters Testis Germ Cell Content, but Does Not Impact Fertility in Mice. <i>Endocrinology</i> , 2022, 163, .	1.4	2
2	Inhibin Inactivation in Female Mice Leads to Elevated FSH Levels, Ovarian Overstimulation, and Pregnancy Loss. <i>Endocrinology</i> , 2022, 163, .	1.4	5
3	Structure of AMH bound to AMHR2 provides insight into a unique signaling pair in the TGF- β family. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	26
4	TGFBR3L is an inhibin B co-receptor that regulates female fertility. <i>Science Advances</i> , 2021, 7, eabl4391.	4.7	21
5	TMEPAI/PMEP1 Is a Positive Regulator of Skeletal Muscle Mass. <i>Frontiers in Physiology</i> , 2020, 11, 560225.	1.3	5
6	Engineering the Ovarian Hormones Inhibin A and Inhibin B to Enhance Synthesis and Activity. <i>Endocrinology</i> , 2020, 161, .	1.4	8
7	New insights into the genetic basis of premature ovarian insufficiency: Novel causative variants and candidate genes revealed by genomic sequencing. <i>Maturitas</i> , 2020, 141, 9-19.	1.0	41
8	A variant of human growth differentiation factor-9 that improves oocyte developmental competence. <i>Journal of Biological Chemistry</i> , 2020, 295, 7981-7991.	1.6	28
9	Activin A-Induced Cachectic Wasting Is Attenuated by Systemic Delivery of Its Cognate Propeptide in Male Mice. <i>Endocrinology</i> , 2019, 160, 2417-2426.	1.4	17
10	Serum Concentrations of Oocyte-Secreted Factors BMP15 and GDF9 During IVF and in Women With Reproductive Pathologies. <i>Endocrinology</i> , 2019, 160, 2298-2313.	1.4	19
11	Inhibin: To Betaglycan, or Not to Betaglycan. <i>Endocrinology</i> , 2019, 160, 341-342.	1.4	1
12	Functional Characterization of Two New Variants in the Bone Morphogenetic Protein 7 Prodomain in Two Pairs of Monozygotic Twins With Hypospadias. <i>Journal of the Endocrine Society</i> , 2019, 3, 814-824.	0.1	2
13	Cumulin and FSH Cooperate to Regulate Inhibin B and Activin B Production by Human Granulosa-Lutein Cells In Vitro. <i>Endocrinology</i> , 2019, 160, 853-862.	1.4	17
14	Molecular characterization of latent GDF8 reveals mechanisms of activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E866-E875.	3.3	30
15	Structural basis for potency differences between GDF8 and GDF11. <i>BMC Biology</i> , 2017, 15, 19.	1.7	90
16	Multiple Soluble TGF- β Receptors in Addition to Soluble Endoglin Are Elevated in Preeclamptic Serum and They Synergistically Inhibit TGF- β Signaling. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 3065-3074.	1.8	13
17	Specific targeting of TGF- β family ligands demonstrates distinct roles in the regulation of muscle mass in health and disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E5266-E5275.	3.3	90
18	The angiotensin receptor blocker, Losartan, inhibits mammary tumor development and progression to invasive carcinoma. <i>Oncotarget</i> , 2017, 8, 18640-18656.	0.8	66

#	ARTICLE	IF	CITATIONS
19	Targeting TGF- β 2 Mediated SMAD Signaling for the Prevention of Fibrosis. <i>Frontiers in Pharmacology</i> , 2017, 8, 461.	1.6	393
20	BMP15 Mutations Associated With Primary Ovarian Insufficiency Reduce Expression, Activity, or Synergy With GDF9. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 1009-1019.	1.8	31
21	A Novel, More Efficient Approach to Generate Bioactive Inhibins. <i>Endocrinology</i> , 2016, 157, 2799-2809.	1.4	10
22	Smad7 gene delivery prevents muscle wasting associated with cancer cachexia in mice. <i>Science Translational Medicine</i> , 2016, 8, 348ra98.	5.8	70
23	Differential Effects of IL6 and Activin A in the Development of Cancer-Associated Cachexia. <i>Cancer Research</i> , 2016, 76, 5372-5382.	0.4	62
24	The TGF- β 2 Signalling Network in Muscle Development, Adaptation and Disease. <i>Advances in Experimental Medicine and Biology</i> , 2016, 900, 97-131.	0.8	56
25	Biological activity and in vivo half-life of pro-activin A in male rats. <i>Molecular and Cellular Endocrinology</i> , 2016, 422, 84-92.	1.6	14
26	Development of a high-throughput assay for human proprotein convertase 5/6 for detecting uterine receptivity. <i>Analytical Biochemistry</i> , 2015, 475, 14-21.	1.1	5
27	Inhibin Biosynthesis and Activity Are Limited by a Prodomain-Derived Peptide. <i>Endocrinology</i> , 2015, 156, 3047-3057.	1.4	10
28	Development of Novel Activin-Targeted Therapeutics. <i>Molecular Therapy</i> , 2015, 23, 434-444.	3.7	46
29	Germline Mutations of Inhibins in Early-Onset Ovarian Epithelial Tumors. <i>Human Mutation</i> , 2014, 35, 294-297.	1.1	11
30	Elevated expression of activins promotes muscle wasting and cachexia. <i>FASEB Journal</i> , 2014, 28, 1711-1723.	0.2	163
31	Use of detergent-based buffers allows detection of precursor inhibin forms in an immunoassay format. <i>Molecular and Cellular Endocrinology</i> , 2013, 381, 106-114.	1.6	6
32	Identification of protein binding partners of ALK-5 kinase inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 6496-6500.	1.4	2
33	Species Differences in the Expression and Activity of Bone Morphogenetic Protein 15. <i>Endocrinology</i> , 2013, 154, 888-899.	1.4	28
34	Activation of Latent Human GDF9 by a Single Residue Change (Gly391Arg) in the Mature Domain. <i>Endocrinology</i> , 2012, 153, 1301-1310.	1.4	40
35	Activin Signaling Regulates Sertoli Cell Differentiation and Function. <i>Endocrinology</i> , 2012, 153, 6065-6077.	1.4	61
36	New insights into the mechanisms of activin action and inhibition. <i>Molecular and Cellular Endocrinology</i> , 2012, 359, 2-12.	1.6	81

#	ARTICLE	IF	CITATIONS
37	HtrA3 as an Early Marker for Preeclampsia: Specific Monoclonal Antibodies and Sensitive High-Throughput Assays for Serum Screening. PLoS ONE, 2012, 7, e45956.	1.1	28
38	The Synthesis and Secretion of Inhibins. Vitamins and Hormones, 2011, 85, 149-184.	0.7	23
39	2-Phenyl and 2-heterocyclic-4-(3-(pyridin-2-yl)-1H-pyrazol-4-yl)pyridines as inhibitors of TGF- β 1 and activin A signalling. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 5642-5645.	1.0	8
40	Generation of a Specific Activin Antagonist by Modification of the Activin A Propeptide. Endocrinology, 2011, 152, 3758-3768.	1.4	23
41	Hormonal Regulation of Sertoli Cell Micro-RNAs at Spermiation. Endocrinology, 2011, 152, 1670-1683.	1.4	78
42	Prodomains regulate the synthesis, extracellular localisation and activity of TGF- β 2 superfamily ligands. Growth Factors, 2011, 29, 174-186.	0.5	99
43	Two Distinct Regions of Latency-associated Peptide Coordinate Stability of the Latent Transforming Growth Factor- β 1 Complex. Journal of Biological Chemistry, 2010, 285, 17029-17037.	1.6	96
44	Inhibin B Is a More Potent Suppressor of Rat Follicle-Stimulating Hormone Release than Inhibin A in Vitro and in Vivo. Endocrinology, 2009, 150, 4784-4793.	1.4	38
45	A Common Biosynthetic Pathway Governs the Dimerization and Secretion of Inhibin and Related Transforming Growth Factor β 2 (TGF β 2) Ligands. Journal of Biological Chemistry, 2009, 284, 9311-9320.	1.6	63
46	Suppression of Inhibin A Biological Activity by Alterations in the Binding Site for Betaglycan. Journal of Biological Chemistry, 2008, 283, 16743-16751.	1.6	42